Top

Infectious Agents and Cancer

Published in:

Open Access 01-12-2021 | Human Papillomavirus | Research Article

The prevalence and distribution of human papillomavirus among 10,867 Chinese Han women

Authors: Chunlei Guo, Hui Du, Jerome L. Belinson, Chun Wang, Xia Huang, Xinfeng Qu, Ruifang Wu, CHIMUST team

Published in: Infectious Agents and Cancer | Issue 1/2021

Abstract

Objective

To assess the prevalence and distribution of HPV genotypes among Chinese Han women, and to explore the risk of high-grade cervical lesions associated with individual hr-HPV genotypes.

Methods

Genotyping and histopathology data from the Chinese Multi-Center Screening Trial (CHIMUST) and its pilot screening trial, from 6 regions across mainland China, were re-analyzed. The data from physician- and self-collected samples from 10,867 Chinese Han women (ages 30–69) were used to determine the prevalence and distribution of hr-HPV and to explore the risk association between hr-HPV genotypes and precancerous lesions.

Results

9.2% of the study population tested hr-HPV positive in physician-collected sample. The prevalence varied regionally from the lowest in Guangdong (6.3%) to the highest in Inner Mongolia (13.0%). The most prevalent genotypes found were HPV-52 (21.7%), HPV-16 (19.2%), HPV-58 (15.0%), HPV-39 (8.9%), and HPV-51 (8.2%). The overall odds ratios for CIN2+ and CIN3+ for the presence of HPV-16 was 58.6 (95% CI 39.2–87.5) and, 91.6 (95%CI 54.3–154.6), respectively and remained the highest odds ratio for CIN3+ in all 6 regions.

Conclusion

Geographical variation exists in the prevalence and distribution of hr-HPV in mainland China. HPV-16/52/58 were the most prevalent genotypes, and HPV-16 had the highest risk for high-grade cervical lesions.

Trial registration

CHIMUST, Registration number: ChiCTR-EOC-16008456. Registered 11 May 2016.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA Cancer J Clin. 2020 Jul;70(4):313]. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRef

Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–203. https://doi.org/10.1016/S2214-109X(19)30482-6.CrossRefPubMed

Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.CrossRefPubMed

Harden ME, Munger K. Human papillomavirus molecular biology. Mutat Res Rev Mutat Res. 2017;772:3–12. https://doi.org/10.1016/j.mrrev.2016.07.002.CrossRefPubMed

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1–441.PubMedCentral

de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70. https://doi.org/10.1002/ijc.30716.CrossRefPubMedPubMedCentral

Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of HPV-related disease. Best Pract Res Clin Obstet Gynaecol. 2018;47:14–26. https://doi.org/10.1016/j.bpobgyn.2017.08.006.CrossRefPubMed

Belinson JL, Pretorius RG. A Standard Protocol for the Colposcopy Exam. J Low Genit Tract Dis. 2016;20(4):e61–2. https://doi.org/10.1097/LGT.0000000000000239.CrossRefPubMed

Duan L, Du H, Wang C, et al. The effectiveness of HPV viral load, reflected by Cobas 4800 HPV-Ct values for the triage of HPV-positive women in primary cervical cancer screening: Direct endocervical samples. PLoS One. 2020;15(5):e0232107. Published 2020 May 7. https://doi.org/10.1371/journal.pone.0232107.CrossRefPubMedPubMedCentral

10.

Duan L, Du H, Wang C, et al. The application of BMRT-HPV viral load to secondary screening strategies for cervical cancer. PLoS One. 2020;15(5):e0232117. Published 2020 May 1. https://doi.org/10.1371/journal.pone.0232117.CrossRefPubMedPubMedCentral

11.

Yi X, Zou J, Xu J, Liu T, Liu T, Hua S, Xi F, Nie X, Ye L, Luo Y, Xu L, du H, Wu R, Yang L, Liu R, Yang B, Wang J, Belinson JL. Development and validation of a new HPV genotyping assay based on next-generation sequencing. Am J Clin Pathol. 2014;141(6):796–804. https://doi.org/10.1309/AJCP9P2KJSXEKCJB.CrossRefPubMed

12.

WHO Director-General. WHO Director-General calls for all countries to take action to help end the suffering caused by cervical cancer. https://www.who.int/reproductivehealth/call-to-action-elimination-cervical-cancer/en/,2020-07-10.

13.

Simms KT, Steinberg J, Caruana M, Smith MA, Lew JB, Soerjomataram I, Castle PE, Bray F, Canfell K. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. Lancet Oncol. 2019;20(3):394–407. https://doi.org/10.1016/S1470-2045(18)30836-2.CrossRefPubMed

14.

Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Luxembourg A. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143–59. https://doi.org/10.1016/S0140-6736(17)31821-4.CrossRefPubMed

15.

Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, de Sanjosé S, Castellsagué X. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis [published correction appears in Lancet Glob Health. 2017 Jul;5(7): e662]. Lancet Glob Health. 2016;4(7):e453–63. https://doi.org/10.1016/S2214-109X(16)30099-7.CrossRefPubMed

16.

Hildesheim A, Gonzalez P, Kreimer AR, et al. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am J Obstet Gynecol. 2016;215(2):212. e1–e15. https://doi.org/10.1016/j.ajog.2016.02.021.CrossRef

17.

Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER, American Cancer Society, American Society for Colposcopy and Cervical Pathology, American Society for Clinical Pathology. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137(4):516–42. https://doi.org/10.1309/AJCPTGD94EVRSJCG.CrossRefPubMed

18.

Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FAR, Kinney WK, Massad LS, Mayeaux EJ, Saslow D, Schiffman M, Wentzensen N, Lawson HW, Einstein MH. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015;136(2):178–82. https://doi.org/10.1016/j.ygyno.2014.12.022.CrossRefPubMed

19.

Cheung LC, Egemen D, Chen X, Katki HA, Demarco M, Wiser AL, Perkins RB, Guido RS, Wentzensen N, Schiffman M. 2019 ASCCP Risk-Based Management Consensus Guidelines: Methods for Risk Estimation, Recommended Management, and Validation. J Low Genit Tract Dis. 2020;24(2):90–101. https://doi.org/10.1097/LGT.0000000000000528.CrossRefPubMedPubMedCentral

20.

Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, Huh WK, Kim JJ, Moscicki AB, Nayar R, Saraiya M, Sawaya GF, Wentzensen N, Schiffman M, 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020;24(2):102–31. https://doi.org/10.1097/LGT.0000000000000525.CrossRefPubMedPubMedCentral

21.

Ogilvie GS, van Niekerk D, Krajden M, Smith LW, Cook D, Gondara L, Ceballos K, Quinlan D, Lee M, Martin RE, Gentile L, Peacock S, Stuart GCE, Franco EL, Coldman AJ. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial [published correction appears in JAMA. 2018 Dec 4;320(21):2273]. JAMA. 2018;320(1):43–52. https://doi.org/10.1001/jama.2018.7464.CrossRefPubMedPubMedCentral

22.

Rebolj M, Rimmer J, Denton K, et al. Primary cervical screening with high risk human papillomavirus testing: observational study. BMJ. 2019;364:l240. Published 2019 Feb 6. https://doi.org/10.1136/bmj.l240.CrossRefPubMedPubMedCentral

23.

Polman NJ, Ebisch RMF, Heideman DAM, Melchers WJG, Bekkers RLM, Molijn AC, Meijer CJLM, Quint WGV, Snijders PJF, Massuger LFAG, van Kemenade FJ, Berkhof J. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Lancet Oncol. 2019;20(2):229–38. https://doi.org/10.1016/S1470-2045(18)30763-0.CrossRefPubMed

24.

Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–99. https://doi.org/10.1086/657321.CrossRefPubMed

25.

Li B, Wang H, Yang D, Ma J. Prevalence and distribution of cervical human papillomavirus genotypes in women with cytological results from Sichuan province, China. J Med Virol. 2019;91(1):139–45. https://doi.org/10.1002/jmv.25255.CrossRefPubMed

26.

Cao D, Zhang S, Zhang Q, Wei X, Zhao M, Ma Q, Li Y, Wang L, Pei M, Yang T, Zhao J, Yang X. Prevalence of high-risk human papillomavirus infection among women in Shaanxi province of China: A hospital-based investigation. J Med Virol. 2017;89(7):1281–6. https://doi.org/10.1002/jmv.24748.CrossRefPubMed

27.

Jing L, Zhong X, Zhong Z, Huang W, Liu Y, Yang G, Zhang X, Zou J, Jing C, Wei X. Prevalence of human papillomavirus infection in Guangdong Province, China: a population-based survey of 78,355 women. Sex Transm Dis. 2014;41(12):732–8. https://doi.org/10.1097/OLQ.0000000000000201.CrossRefPubMed

28.

Li K, Li Q, Song L, Wang D, Yin R. The distribution and prevalence of human papillomavirus in women in mainland China. Cancer. 2019;125(7):1030–7. https://doi.org/10.1002/cncr.32003.CrossRefPubMed

29.

Wang X, Ji Y, Li J, Dong H, Zhu B, Zhou Y, Wang J, Zhou X, Wang Y, Peppelenbosch MP, Pan Q, Ji X, Liu D. Prevalence of human papillomavirus infection in women in the Autonomous Region of Inner Mongolia: A population-based study of a Chinese ethnic minority. J Med Virol. 2018;90(1):148–56. https://doi.org/10.1002/jmv.24888.CrossRefPubMed

30.

Zhao P, Liu S, Zhong Z, et al. Prevalence and genotype distribution of human papillomavirus infection among women in northeastern Guangdong Province of China. BMC Infect Dis. 2018;18(1):204. Published 2018 May 3. https://doi.org/10.1186/s12879-018-3105-x.CrossRefPubMedPubMedCentral

31.

Zhong TY, Zhou JC, Hu R, Fan XN, Xie XY, Liu ZX, Lin M, Chen YG, Hu XM, Wang WH, Li L, Xiao HP. Prevalence of human papillomavirus infection among 71,435 women in Jiangxi Province, China. J Infect Public Health. 2017;10(6):783–8. https://doi.org/10.1016/j.jiph.2017.01.011.CrossRefPubMed

32.

Xiang F, Guan Q, Liu X, Xiao H, Xia Q, Liu X, Sun H, Song X, Zhong Y, Yuan CH, Xiang Y. Distribution characteristics of different human papillomavirus genotypes in women in Wuhan, China. J Clin Lab Anal. 2018;32(8):e22581. https://doi.org/10.1002/jcla.22581.CrossRefPubMedPubMedCentral

33.

Wu RF, Dai M, Qiao YL, Clifford GM, Liu ZH, Arslan A, Li N, Shi JF, Snijders PJF, Meijer CJLM, Franceschi S. Human papillomavirus infection in women in Shenzhen City, People's Republic of China, a population typical of recent Chinese urbanisation. Int J Cancer. 2007;121(6):1306–11. https://doi.org/10.1002/ijc.22726.CrossRefPubMed

34.

Chen X, Wallin KL, Duan M, Gharizadeh B, Zheng B, Qu P. Prevalence and genotype distribution of cervical human papillomavirus (HPV) among women in urban Tianjin, China. J Med Virol. 2015;87(11):1966–72. https://doi.org/10.1002/jmv.24248.CrossRefPubMed

35.

Burk RD, Harari A, Chen Z. Human papillomavirus genome variants. Virology. 2013;445(1–2):232–43. https://doi.org/10.1016/j.virol.2013.07.018.CrossRefPubMedPubMedCentral

36.

Mirabello L, Yeager M, Cullen M, et al. HPV16 Sublineage Associations With Histology-Specific Cancer Risk Using HPV Whole-Genome Sequences in 3200 Women. J Natl Cancer Inst. 2016;108(9):djw100. Published 2016 Apr 29. https://doi.org/10.1093/jnci/djw100.CrossRefPubMedPubMedCentral

37.

Mirabello L, Yeager M, Yu K, et al. HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. Cell. 2017;170(6):1164–1174.e6. https://doi.org/10.1016/j.cell.2017.08.001.CrossRefPubMedPubMedCentral

38.

Chan PK, Ho WC, Chan MC, et al. Meta-analysis on prevalence and attribution of human papillomavirus types 52 and 58 in cervical neoplasia worldwide. PLoS One. 2014;9(9):e107573. Published 2014 Sep 17. https://doi.org/10.1371/journal.pone.0107573.CrossRefPubMedPubMedCentral

39.

Zhang C, Cheng W, Liu Q, Guan Q, Zhang Q. Distribution of human papillomavirus infection: a population-based study of cervical samples from Jiangsu Province. Virol J. 2019;16(1):67. Published 2019 May 20. https://doi.org/10.1186/s12985-019-1175-z.CrossRefPubMedPubMedCentral

40.

Yuan XW, Li YJ, Qiu Q, Luo ZY, Zhao XF. Prevalence and genotype distribution of human papillomavirus among 9945 women from the Nanhai area of Foshan. BMC Infect Dis. 2019;19(1):71. Published 2019 Jan 18. https://doi.org/10.1186/s12879-019-3687-y.CrossRefPubMedPubMedCentral

41.

Liu H, Wei X, Xie Z, Wang X, Gong X, Ke W, Zou H. Cervical human papillomavirus among 19 753 women attending gynecological department of a major comprehensive hospital in north Anhui China 2013-2016: Implication for cervical cancer screening and prevention. J Med Virol. 2019;91(4):698–706. https://doi.org/10.1002/jmv.25365.CrossRefPubMed

42.

Long W, Yang Z, Li X, et al. HPV-16, HPV-58, and HPV-33 are the most carcinogenic HPV genotypes in Southwestern China and their viral loads are associated with severity of premalignant lesions in the cervix. Virol J. 2018;15(1):94. Published 2018 May 25. https://doi.org/10.1186/s12985-018-1003-x.CrossRefPubMedPubMedCentral

43.

He J, Yang Y, Chen Z, et al. Identification of variants and therapeutic epitopes in HPV-33/HPV-58 E6 and E7 in Southwest China. Virol J. 2019;16(1):72. Published 2019 May 28. https://doi.org/10.1186/s12985-019-1168-y.CrossRefPubMedPubMedCentral

44.

Lagheden C, Eklund C, Lamin H, Kleppe SN, Lei J, Elfström KM, Sundström K, Andrae B, Sparén P, Dillner J. Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer. Br J Cancer. 2018;118(10):1377–81. https://doi.org/10.1038/s41416-018-0053-6.CrossRefPubMedPubMedCentral

45.

Chen W, Sun H, Molijn A, Zeng L, Kang L, Jenkins D, Zhang S, Cui J, Wu Z, Pirog E, Shen G, Zhang X, Qiao Y, Chinese HPV Typing Group. The Variable Characteristics of Human Papillomavirus in Squamous Cell Carcinoma and Adenocarcinoma of Cervix in China. J Low Genit Tract Dis. 2018;22(4):355–61. https://doi.org/10.1097/LGT.0000000000000408.CrossRefPubMed

Title: The prevalence and distribution of human papillomavirus among 10,867 Chinese Han women
Authors: Chunlei Guo
Hui Du
Jerome L. Belinson
Chun Wang
Xia Huang
Xinfeng Qu
Ruifang Wu
CHIMUST team
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Human Papillomavirus
Cervical Cancer
Cervical Cancer
Colposcopy
Colposcopy
Published in: Infectious Agents and Cancer / Issue 1/2021
Electronic ISSN: 1750-9378
DOI: https://doi.org/10.1186/s13027-021-00360-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2021

Authors’ response to “Evaluation of Treatments for HIV-Associated Kaposi Sarcoma in Africa”

Low expression of NSD1, NSD2, and NSD3 define a subset of human papillomavirus-positive oral squamous carcinomas with unfavorable prognosis

Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab

Emerging role of human polyomaviruses 6 and 7 in human cancers

Correction to: Discrepancy of p16 immunohistochemical expression and HPV RNA in penile cancer. A multiplex in situ hybridization/immunohistochemistry approach study

Type-specific persistence, clearance and incidence of high-risk HPV among screen-positive Rwandan women living with HIV

Keynote webinar | Spotlight on antibody–drug conjugates in cancer